ClinicalTrials.gg
RecruitingNCT04600063ISOP-DPUpdated Oct 23, 2020

Isolation Procedure vs. Conventional Procedure During Distal Pancreatectosplenectomy for Pancreatic Cancer

An interventional study of Isolation procedure (RAMPS procedure) and Conventional procedure in Resectable Pancreatic Body/Tail Carcinoma, sponsored by Wakayama Medical University. Recruiting at 10 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Wakayama Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

In the distal pancreatectomy (including pancreatic tail resection) for invasive ductal carcinoma of the pancreas, we evaluate the usefulness of a procedure of firstly transection of splenic arteries and veins (the isolation procedure group) compared to a conventional procedure of transection of the splenic vein at the end.

02

Conditions studied

  • Resectable Pancreatic Body/Tail Carcinoma
03

In context

Lead sponsor

Wakayama Medical University is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resectable pancreatic cancer (Adenocarcinoma, adenosquamous cell carcinoma, mucinous carcinoma, and anaplastic carcinoma according to the 7th edition of the regulations for handling pancreatic cancer)
  • ASA-PS (American Society of Anesthesiology, General condition classification) is Class 1-3.
  • Age are over 20 years old.
  • Able to understand the content of the research and has obtained written consent from the person himself/herself.

Exclusion criteria

Exclusion Criteria:

  • Non-resectable pancreatic cancer by image diagnosis at the initial diagnosis
  • Cases suspected of portal vein (superior mesenteric vein) invasion
  • Patients with severe ischemic heart disease
  • Patients with cirrhosis or active hepatitis requiring treatment
  • Patients with dyspnea requiring oxygen administration
  • Patients undergoing dialysis due to chronic renal failure
  • Cases in which arterial reconstruction of the superior mesenteric artery, common hepatic artery, celiac artery, etc. is considered necessary
  • Patients with strong suspected paraaortic lymph node
  • Active double cancer thought to affect adverse events and prognosis
  • Long-term oral that may affect adverse events
  • Patients who are considered to have difficulty participating in the study due to psychosis or psychiatric symptoms.
  • Cases other than invasive pancreatic ductal carcinoma by preoperative . Invasive intraductal papillary mucinous carcinoma (IPMC) is excluded.
  • Patients who cannot use both iodine drugs and gadnium drugs due to severe drug allergy
  • Cases where the prescribed procedure is difficult due to history of upper abdominal surgery such as stomach, spleen, kidney, liver, transverse colon, retroperitoneum including pancreas and pancreatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Conventional procedure

    In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.

    Procedure: Isolation procedure (RAMPS procedure) · Procedure: Conventional procedure

  • Experimental
    Isolation procedure (RAMPS procedure)

    In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).

    Procedure: Isolation procedure (RAMPS procedure) · Procedure: Conventional procedure

Interventions

  • ProcedureIsolation procedure (RAMPS procedure)

    In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).

  • ProcedureConventional procedure

    In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.

06

What researchers measure

Primary outcomes

  1. 2-year recurrence-free survival

    Until 2 years after last entry case undergo surgery

    Time frame: Up to 24 months

07

Study locations

1 of 10 sites recruiting
  • Kobe University
    Kobe, Hyogo, Japan
    Not yet recruiting
    • Hirochika Toyama, M.D., PhD. · Contact
    • Hirochika Toyama, M.D., PhD. · Sub investigator
  • Nara Medical University
    Kashihara, Nara, Japan
    Not yet recruiting
    • Masayuki Sho, M.D., PhD. · Contact
  • Kinki University
    Sayama, Osaka, Japan
    Not yet recruiting
    • Ippei Matsumoto, M.D., PhD · Contact
  • Osaka University
    Suita, Osaka, Japan
    Not yet recruiting
    • Hidetoshi Eguchi, M.D., Ph.D. · Contact
  • Shiga Medical University
    Ōtsu, Shiga, Japan
    Not yet recruiting
    • Masaji Tani, M.D., Ph.D. · Contact
  • Kumamoto University
    Kumamoto, Japan
    Not yet recruiting
    • Hideo Baba · Contact
  • Osaka City University
    Osaka, Japan
    Not yet recruiting
    • Ryosuke Amano, M.D., PhD. · Contact
    • Ryosuke Amano, M.D., PhD. · Sub investigator
  • Jikei University
    Tokyo, Japan
    Not yet recruiting
  • Toyama University
    Toyama, Japan
    Not yet recruiting
    • Tsutomu Fujii · Contact
  • Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1 Kimiidera
    Wakayama, 641-8510, Japan
    Recruiting
    • Ken-ichi Okada, MD · Contactokada@wakayama-med.ac.jp · +81-73-441-0613
    • Ken-ichi Okada, MD, PhD · Principal investigator
08

References and documents

Publications

  • Okada KI, Kawai M, Hirono S, Sho M, Tani M, Matsumoto I, Yamada S, Amano R, Toyama H, Yamashita YI, Gocho T, Shibuya K, Nagai M, Maehira H, Kamei K, Ohira G, Shirai Y, Takami H, Kimura N, Fukumoto T, Baba H, Kodera Y, Nakao A, Shimokawa T, Katsuda M, Yamaue H. ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial. Trials. 2021 Sep 16;22(1):633. doi: 10.1186/s13063-021-05523-y. PubMed 34530885 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Sep 2024, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2020
First posted
Oct 23, 2020
StartActual
Oct 1, 2020
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2025
Last update
Oct 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04600063
Lead sponsor
Wakayama Medical University
Responsible party
Hiroki Yamaue (Director, Principal Investigator, Professor of Second Department of Surgery, Wakayama Medical University) — Principal investigator
First posted
Oct 23, 2020
Start date
Oct 1, 2020
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Oct 23, 2020

Study contacts

Ken-ichi Okada
Contact
okada@wakayama-med.ac.jp
+81734410613 ext. 5112

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion